

Paediatric Diseases Working Party

for Blood and Marrow Transplantation

Chair: Selim Corbacioglu

Clinical Trial Committee Chair: Marc Ansari Vice Chair: Josu de la Fuente Statistician: Jacques-Emmanuel Galimard Study coordinator: Arnaud Dalissier


Paediatric patients transplanted between 2000 and 2016

Patient Characteristics				N.I.	0/
Total number of HSCT				N 61112	%
Total number of patients				52665	
rotal frames of patients				3233	
Ratio HSCT/Patients				1,16	
Median age in years at				4.91(0-17.9)	
diagnosis(Min-Max)				T.31(0-17.3)	
Median age in years at HSCT (Min-Max)				7.61(0-17.9)	
Canadan	Mala			24220	F0 F
Gender	Male			31326	59.5
	Female			21077	40.2
Diagnosis	Malignan	t diseases			
ag.10010	mangilan	Acute leuk	aemia	17850	33.9
		Chronic leuk		827	1.6
			ohoma	3298	6.3
	F	Plasma cell disc	29	0.1	
		Solid tu	12232	23.2	
	Myelodysplas	tic/Myeloprolife	2499	4.7	
	Non Malign	ant diseases			
		Bone marrow	failure	4688	8.9
	Inherited disorders			6135	11.7
	Histiocytic disorders			1036	2.0
	Auto-immune diseases			209	0.4
	Hemoglobinopathies			3817	7.3
Transplant Characteristic	<u>S</u>				
		Malignant	%	Non- malignar disease	nt %
Conditioning regimen	MAC	18086	93.8	10237	77.3
	Non-myeloablative	1203	6.2	3014	22.7
	Missing	17446	0	2634	
Type of transplant	Allogeneic	21033	57.3	15647	98.5
	Autologous	15700	42.7	236	1.5
	Missing	1		2	
-		10010	0.4 =	0074	
Type of cells	BM	12616	34.7	9874	62.9
	PB	20760	57.1	3795	24.2
	Combined	2079	5.7	1666	10.6
	Combined Missing	847 382	2.5	366 175	2.3
	iviissiriy	302		173	
Type of donors (alloHSCT)					
. Jps of deficit (dilot 1001)	Identical sibling	7051	34.6	6716	43.6
	Relative	2682	13.2	2625	17.0
	Unrelated	10650	52.2	6069	39.4
		_			
TBI (age above 2 years old)					
	No	22840	71.8	10334	95.2
	Yes	8990	28.2	523	4.8
	Missing	1637		452	


	Malignant diseases	%	Non malignant diseases	%
Dead	13055	36.5	2836	18.3
Alive	21126	59.1	11715	75.6
Lost to				
follow up	1553	4.3	926	6
Missing	993		390	
No	11565	75.8	9290	85.3
Yes	3689	24.2	1603	14.7
Missing	21481		4992	
	Alive Lost to follow up Missing No Yes	Dead 13055 Alive 21126 Lost to follow up 1553 Missing 993 No 11565 Yes 3689	Dead 13055 36.5 Alive 21126 59.1 Lost to follow up 1553 4.3 Missing 993 No 11565 75.8 Yes 3689 24.2	Dead 13055 36.5 2836 Alive 21126 59.1 11715 Lost to follow up 1553 4.3 926 Missing 993 390 No 11565 75.8 9290 Yes 3689 24.2 1603

	iviiooirig	21701		100Z	
Outcome Data I					
		Malignant diseases	%	Non-malignant disease	%
Cause of death					
	Relapse or progression	8067	65.8	277	10.5
	Secondary malignancy	93	0.8	23	0.9
	HSCT related	3647	29.7	2008	76.1
	Cell therapy(non HSCT)	0	0	3	0.1
	Other	458	3.7	329	12.5
	Missing	790		196	


Number and type of HSCT for non-malignant diseases from 2000-2016




Number and type of HSCT for malignant diseases from 2000-2016



OS from first graft in malignant* and non-malignant <u>diseases</u>





Please send of your proposal of study to us!

1)The proposal form can be either requested from the WP secretary or can be retrieved from the EBMT website of the PDWP.

2)Completed proposal forms should then be emailed to the PDWP chair, vice-chair, the secretary, and the Clinical Trials Committee chair Marc Ansari(Marc.Ansari@hcuge.ch)

Time in years

^{*}Plasma cell disorders were not shown in these graphs